Etoiles Capital Group Co., Ltd (EFTY)

Oncternal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	1.44	0.07
Cash & Short-Term Investments	1.44	0.07
Cash Growth	1944.70%	-
Receivables	0.01	-
Prepaid Expenses	0.01	-
Other Current Assets	0.31	-
Total Current Assets	1.77	0.07
Property, Plant & Equipment	0.1	-
Long-Term Deferred Tax Assets	0	-
Long-Term Deferred Charges	0.18	-
Other Long-Term Assets	0.02	-
Total Assets	2.07	0.07
Accrued Expenses	0.02	0.04
Current Portion of Leases	0.05	-
Current Income Taxes Payable	0.15	0
Current Unearned Revenue	0.96	-
Total Current Liabilities	1.18	0.04
Long-Term Leases	0	-
Total Liabilities	1.18	0.04
Common Stock	0	0
Additional Paid-In Capital	0	0
Retained Earnings	0.88	0.03
Comprehensive Income & Other	0	0
Shareholders' Equity	0.89	0.03
Total Liabilities & Equity	2.07	0.07
Total Debt	0.05	-
Net Cash (Debt)	1.39	0.07
Net Cash Growth	1868.91%	-
Net Cash Per Share	0.08	0.00
Filing Date Shares Outstanding	19.9	18.5
Total Common Shares Outstanding	18.5	18.5
Working Capital	0.59	0.03
Book Value Per Share	0.05	0.00
Tangible Book Value	0.89	0.03
Tangible Book Value Per Share	0.05	0.00
Machinery	0	-
Leasehold Improvements	0.07	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q